Budar-Fernández LF, Bienvenú-Ramírez S, Reyes-Ruiz JM, Martínez-Mier G

Language: Spanish
References: 17
Page: 153-159
PDF size: 299.51 Kb.

ABSTRACT

Introduction: renal transplantation is considered the best treatment option for chronic kidney disease. Despite advances in immunosuppression, graft failure and graft loss due to acute graft rejection remains substantially high and relevant. Objective: to determine the proportion of patients with graft loss and mortality after antibody-mediated renal rejection treated with plasmapheresis in a tertiary hospital of the Mexican Social Security Institute (IMSS). Material and methods: observational, descriptive, cross-sectional, retrospective study, conducted in patients with a diagnosis of antibody-mediated renal graft rejection in the period from January 2018 to December 2022, who received plasmapheresis as part of the treatment. Graft survival was assessed by Kaplan-Meier curve. t Student was used for analysis of normally distributed quantitative variables. A value of p < 0.05 was considered as a statistically significant difference. Results: we included 54 patients, mostly men (72.2%), with a mean age of 38.63 ± 10.9 years. The most frequent comorbidity was hypertension (56.4%) and in most of them the cause of renal disease was not determined (75.9%). Graft survival at 48 months was 59.3% (32 patients), of those who had graft loss 16 (29.6%) started hemodialysis and 6 (11.1%) peritoneal dialysis; the average time in which they had graft loss was 33.5 ± 19.2 months. Among the complications, respiratory tract infectious complications were the most frequent (9.3%). Mortality was three patients (5.6%) of whom 2 (3.7%) had graft loss and were already on hemodialysis and 1 (1.9%) died with a functioning graft. Conclusion: the graft survival found in this study is similar to that reported in other centers, both national and international. Due to the small sample size, the variables analyzed did not show statistical significance for graft survival.

REFERENCES

1. Xie P, Tao M, Peng K, Zhao H, Zhang K, Sheng Y et al. Plasmapheresis therapy in kidney transplant rejection. Blood Purif. 2019; 47 (1-3): 73-84.

2. Pratschke J, Dragun D, Hauser IA, Horn S, Mueller TF, Schemmer P et al. Immunological risk assessment: the key to individualized immunosuppression after kidney transplantation. Transplant Rev. 2016; 30 (2): 77-84.

3. Montgomery RA, Loupy A, Segev DL. Antibody-mediated rejection: new approaches in prevention and management. Am J Transplant. 2018; 18 (S3): 3-17.

4. Chen YY, Sun X, Huang W, He FF, Zhang C. Therapeutic apheresis in kidney diseases: an updated review. Ren Fail. 2022; 44 (1): 842-857.

5. Bestard O, Thaunat O, Bellini MI, Bohmig GA, Budde K, Claas F et al. Alloimmune risk stratification for kidney transplant rejection. Transpl Int. 2022; 35: 10138. (Consultado el 24 de octubre de 2022) Available in: https://www.frontierspartnerships.org/articles/10.3389/ti.2022.10138/full

6. Lan JH, Kadatz M, Chang DT, Gill J, Gebel HM, Gill JS. Pretransplant calculated panel reactive antibody in the absence of donor-specific antibody and kidney allograft survival. Clin J Am Soc Nephrol CJASN. 2021; 16 (2): 275-283.

7. Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation. 2020; 104 (5): 911-922.

8. Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol. 2020; 15 (3): 430-438.

9. Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012; 25 (6): 623-632.

10. Piñeiro GJ, De Sousa-Amorim E, Solé M, Ríos J, Lozano M, Cofán F et al. Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection. BMC Nephrol. 2018; 19 (1): 261.

11. Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012; 25 (6): 623-632.

12. Roufosse C, Becker JU, Rabant M, Seron D, Bellini MI, Böhmig GA et al. Proposed definitions of antibody-mediated rejection for use as a clinical trial endpoint in kidney transplantation. Transpl Int. 2022; 35: 10140. (Consultado el 30 de septiembre de 2022) Available in: https://www.frontierspartnerships.org/articles/10.3389/ti.2022.10140/full

13. Brown CM, Abraham KA, O'Kelly P, Conlon PJ, Walshe JJ. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Transplant Proc. 2009; 41 (9): 3690-3692.

14. Yamada C, Ramon DS, Cascalho M, Sung RS, Leichtman AB, Samaniego M et al. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion (Paris). 2015; 55 (4): 727-735; quiz 726.

15. Akagun T, Yazici H, Caliskan Y, Ozluk Y, Sahin S, Turkmen A et al. The effect of histopathologic and clinical features on allograft survival in renal transplant patients with antibody-mediated rejection. Ren Fail. 2017; 39 (1): 19-25.

16. Yilmaz VT, Dandin O, Kisaoglu A, Avanaz A, Kamaci D, Toru HS et al. Prognosis and treatment for active and chronic antibody-mediated rejection in renal transplant recipients; single center experience. Transplant Proc. 2022; 54 (7): 1809-1815.

17. Alalawi F, Seddik AA, Gulzar K, Ahmed MT, Kovilazhikam D, Sony L et al. Therapeutic plasma exchange: indications and outcomes. Single-Center Registry. Eur J Clin Med. 2022; 3 (1): 31-36.